BIO-TECHNE Corp Amortization of Intangible Assets
BIO-TECHNE Corp (TECH) reported Amortization of Intangible Assets of $61.79 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-24
- BIO-TECHNE Corp amortization of intangible assets for the quarter ending 2026-06-30 was $15.23M, a 14.34% decline year-over-year.
- BIO-TECHNE Corp amortization of intangible assets for the quarter ending 2026-03-31 was $15.53M, a 18.92% decline year-over-year.
- BIO-TECHNE Corp amortization of intangible assets for the quarter ending 2025-12-31 was $15.53M, a 17.71% decline year-over-year.
- BIO-TECHNE Corp amortization of intangible assets for the quarter ending 2025-09-30 was $15.50M, a 22.66% decline year-over-year.
- BIO-TECHNE Corp amortization of intangible assets for fiscal 2026 was $61.79M, a 18.75% decline from fiscal 2025.
- BIO-TECHNE Corp amortization of intangible assets for fiscal 2025 was $76.04M, a 4.77% decline from fiscal 2024.
- BIO-TECHNE Corp amortization of intangible assets for fiscal 2024 was $79.85M, a 3.05% increase from fiscal 2023.
- BIO-TECHNE Corp amortization of intangible assets for fiscal 2023 was $77.49M, a 4.51% increase from fiscal 2022.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $15.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $30.76M derived: sum of 2 quarters · filed 2026-08-24 | $46.29M derived: sum of 3 quarters · filed 2026-08-24 | $61.79M 10-K · filed 2026-08-24 | |
| 2026-03-31 | $15.53M 10-Q · filed 2026-05-06 | $31.06M derived: sum of 2 quarters · filed 2026-05-06 | $46.56M 10-Q · filed 2026-05-06 | $64.34M derived: sum of 4 quarters · filed 2026-08-24 | |
| 2025-12-31 | $15.53M 10-Q · filed 2026-02-04 | $31.03M 10-Q · filed 2026-02-04 | $48.80M derived: sum of 3 quarters · filed 2026-08-24 | $67.96M derived: sum of 4 quarters · filed 2026-08-24 | |
| 2025-09-30 | $15.50M 10-Q · filed 2025-11-05 | $33.27M derived: sum of 2 quarters · filed 2026-08-24 | $52.43M derived: sum of 3 quarters · filed 2026-08-24 | $71.30M derived: sum of 4 quarters · filed 2026-08-24 | |
| 2025-06-30 | $17.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $36.93M derived: sum of 2 quarters · filed 2026-08-24 | $55.80M derived: sum of 3 quarters · filed 2026-08-24 | $76.04M 10-K · filed 2026-08-24 | |
| 2025-03-31 | $19.16M 10-Q · filed 2026-05-06 | $38.03M derived: sum of 2 quarters · filed 2026-05-06 | $58.27M 10-Q · filed 2026-05-06 | $57.71M 10-Q · filed 2025-05-08 | $77.87M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $18.87M 10-Q · filed 2026-02-04 | $38.91M 10-Q · filed 2026-02-04 | $58.71M derived: sum of 3 quarters · filed 2026-02-04 | $78.38M derived: sum of 4 quarters · filed 2026-02-04 | |
| 2024-09-30 | $20.04M 10-Q · filed 2024-11-05 | $39.84M derived: sum of 2 quarters · filed 2025-08-22 | $59.51M derived: sum of 3 quarters · filed 2025-08-22 | $79.66M derived: sum of 4 quarters · filed 2025-08-22 | |
| 2024-06-30 | $19.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $39.47M derived: sum of 2 quarters · filed 2025-08-22 | $59.62M derived: sum of 3 quarters · filed 2025-08-22 | $79.85M 10-K · filed 2025-08-22 | |
| 2024-03-31 | $19.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-06 | $39.83M derived: sum of 2 quarters · filed 2024-05-06 | $60.06M 10-Q · filed 2024-05-06 | $79.15M derived: sum of 4 quarters · filed 2024-08-22 | |
| 2023-12-31 | $20.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07 | $40.38M 10-Q · filed 2024-02-07 | $59.47M derived: sum of 3 quarters · filed 2024-08-22 | $79.01M derived: sum of 4 quarters · filed 2024-08-22 | |
| 2023-09-30 | $20.23M 10-Q · filed 2023-11-07 | $39.32M derived: sum of 2 quarters · filed 2024-08-22 | $58.86M derived: sum of 3 quarters · filed 2024-08-22 | $78.22M derived: sum of 4 quarters · filed 2024-08-22 | |
| 2023-06-30 | $19.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $38.63M derived: sum of 2 quarters · filed 2024-08-22 | $57.99M derived: sum of 3 quarters · filed 2024-08-22 | $77.49M 10-K · filed 2024-08-22 | |
| 2023-03-31 | $19.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08 | $38.90M derived: sum of 2 quarters · filed 2023-05-08 | $58.40M 10-Q · filed 2023-05-08 | ||
| 2022-12-31 | $19.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-07 | $38.86M 10-Q · filed 2023-02-07 | |||
| 2022-09-30 | $19.50M 10-Q · filed 2022-11-07 | ||||
| 2022-06-30 | $74.15M 10-K · filed 2023-08-23 | ||||
| 2022-03-31 | $55.73M 10-Q · filed 2022-05-09 | $92.99M derived: sum of 2 quarters · filed 2022-05-09 | $111.59M derived: sum of 3 quarters · filed 2022-05-09 | $130.30M derived: sum of 4 quarters · filed 2022-08-24 | |
| 2021-12-31 | $37.26M 10-Q · filed 2022-02-07 | $55.86M derived: sum of 2 quarters · filed 2022-02-07 | $74.57M derived: sum of 3 quarters · filed 2022-08-24 | $90.00M derived: sum of 4 quarters · filed 2022-08-24 | |
| 2021-09-30 | $18.61M 10-Q · filed 2021-11-08 | $37.31M derived: sum of 2 quarters · filed 2022-08-24 | $52.74M derived: sum of 3 quarters · filed 2022-08-24 | $67.97M derived: sum of 4 quarters · filed 2022-08-24 | |
| 2021-06-30 | $18.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-24 | $34.14M derived: sum of 2 quarters · filed 2022-08-24 | $49.37M derived: sum of 3 quarters · filed 2022-08-24 | $64.94M 10-K · filed 2022-08-24 | |
| 2021-03-31 | $15.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-07 | $30.66M derived: sum of 2 quarters · filed 2021-05-07 | $46.24M 10-Q · filed 2021-05-07 | $61.71M derived: sum of 4 quarters · filed 2021-08-25 | |
| 2020-12-31 | $15.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-08 | $30.80M 10-Q · filed 2021-02-08 | $46.27M derived: sum of 3 quarters · filed 2021-08-25 | $61.79M derived: sum of 4 quarters · filed 2021-08-25 | |
| 2020-09-30 | $15.57M 10-Q · filed 2020-11-09 | $31.05M derived: sum of 2 quarters · filed 2021-08-25 | $46.56M derived: sum of 3 quarters · filed 2021-08-25 | $61.72M derived: sum of 4 quarters · filed 2021-08-25 | |
| 2020-06-30 | $15.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25 | $30.99M derived: sum of 2 quarters · filed 2021-08-25 | $46.15M derived: sum of 3 quarters · filed 2021-08-25 | $61.09M 10-K · filed 2021-08-25 | |
| 2020-03-31 | $15.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11 | $30.68M derived: sum of 2 quarters · filed 2020-05-11 | $45.63M 10-Q · filed 2020-05-11 | $60.54M derived: sum of 4 quarters · filed 2020-08-26 | |
| 2019-12-31 | $15.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06 | $30.11M 10-Q · filed 2020-02-06 | $45.03M derived: sum of 3 quarters · filed 2020-08-26 | $59.47M derived: sum of 4 quarters · filed 2020-08-26 | |
| 2019-09-30 | $14.95M 10-Q · filed 2019-11-06 | $29.87M derived: sum of 2 quarters · filed 2020-08-26 | $44.31M derived: sum of 3 quarters · filed 2020-08-26 | $59.35M derived: sum of 4 quarters · filed 2020-08-26 | |
| 2019-06-30 | $14.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26 | $29.36M derived: sum of 2 quarters · filed 2020-08-26 | $44.40M derived: sum of 3 quarters · filed 2020-08-26 | $58.72M 10-K · filed 2020-08-26 | |
| 2019-03-31 | $14.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-07 | $29.48M derived: sum of 2 quarters · filed 2019-05-07 | $43.80M 10-Q · filed 2019-05-07 | $56.26M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-12-31 | $15.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-07 | $29.35M 10-Q · filed 2019-02-07 | $41.82M derived: sum of 3 quarters · filed 2019-11-06 | $53.76M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-09-30 | $14.31M 10-Q · filed 2018-11-07 | $26.78M derived: sum of 2 quarters · filed 2019-11-06 | $38.71M derived: sum of 3 quarters · filed 2019-11-06 | $50.01M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-06-30 | $12.46M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-11-06 | $24.40M derived: sum of 2 quarters · filed 2019-11-06 | $35.70M derived: sum of 3 quarters · filed 2019-11-06 | $47.08M 10-K/A · filed 2019-11-06 | |
| 2018-03-31 | $11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $23.23M derived: sum of 2 quarters · filed 2018-05-09 | $34.61M 10-Q · filed 2018-05-09 | $45.50M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2017-12-31 | $11.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08 | $22.68M 10-Q · filed 2018-02-08 | $33.56M derived: sum of 3 quarters · filed 2018-08-27 | $45.25M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2017-09-30 | $11.38M 10-Q · filed 2017-11-09 | $22.27M derived: sum of 2 quarters · filed 2018-08-27 | $33.96M derived: sum of 3 quarters · filed 2018-08-27 | $45.58M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2017-06-30 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27 | $22.58M derived: sum of 2 quarters · filed 2018-08-27 | $34.20M derived: sum of 3 quarters · filed 2018-08-27 | $44.39M 10-K · filed 2018-08-27 | |
| 2017-03-31 | $11.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | $23.32M derived: sum of 2 quarters · filed 2017-05-10 | $33.50M 10-Q · filed 2017-05-10 | $40.46M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-12-31 | $11.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $21.82M 10-Q · filed 2017-02-09 | $28.77M derived: sum of 3 quarters · filed 2018-08-27 | $36.44M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-09-30 | $10.19M 10-Q · filed 2016-11-09 | $17.14M derived: sum of 2 quarters · filed 2018-08-27 | $24.82M derived: sum of 3 quarters · filed 2018-08-27 | $32.18M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-06-30 | $6.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27 | $14.63M derived: sum of 2 quarters · filed 2018-08-27 | $21.99M derived: sum of 3 quarters · filed 2018-08-27 | $29.39M 10-K · filed 2018-08-27 | |
| 2016-03-31 | $7.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | $15.04M derived: sum of 2 quarters · filed 2016-05-10 | $22.44M 10-Q · filed 2016-05-10 | ||
| 2015-12-31 | $7.36M 10-Q · filed 2016-02-09 | $14.77M 10-Q · filed 2016-02-09 | |||
| 2015-09-30 | $7.41M 10-Q · filed 2015-11-09 | ||||
| 2015-03-31 | $6.75M 10-Q · filed 2015-05-11 | $13.61M derived: sum of 2 quarters · filed 2016-02-09 | $19.34M 10-Q · filed 2015-05-11 | ||
| 2014-12-31 | $6.86M 10-Q · filed 2016-02-09 | $12.59M 10-Q · filed 2016-02-09 | |||
| 2014-09-30 | $5.73M 10-Q · filed 2015-11-09 | ||||
| 2014-03-31 | $2.60M 10-Q · filed 2015-05-11 | $5.19M derived: sum of 2 quarters · filed 2015-05-11 | $7.38M 10-Q · filed 2015-05-11 | ||
| 2013-12-31 | $2.59M 10-Q · filed 2015-02-09 | $4.78M 10-Q · filed 2015-02-09 | |||
| 2013-09-30 | $2.19M 10-Q · filed 2014-11-10 | ||||
| 2011-03-31 | $170.00K 10-Q · filed 2011-05-10 | $341.00K derived: sum of 2 quarters · filed 2011-05-10 | $511.00K 10-Q · filed 2011-05-10 | ||
| 2010-12-31 | $171.00K 10-Q · filed 2011-02-09 | $341.00K 10-Q · filed 2011-02-09 | |||
| 2010-09-30 | $170.00K 10-Q · filed 2010-11-09 | ||||
| 2010-03-31 | $240.00K 10-Q · filed 2011-05-10 | $480.00K derived: sum of 2 quarters · filed 2011-05-10 | $720.00K 10-Q · filed 2011-05-10 | ||
| 2009-12-31 | $240.00K 10-Q · filed 2011-02-09 | $480.00K 10-Q · filed 2011-02-09 | |||
| 2009-09-30 | $240.00K 10-Q · filed 2010-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |